reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)

Status: Recruiting
Location: See location...
Intervention Type: Other, Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The purpose of this study is to find out if reSET, an FDA authorized mobile therapeutic, is effective in treating stimulant use disorder and helping keep HIV viral load suppression stable among men who have sex with men who are living with HIV and have a stimulant use disorder.

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• Identifies as male

• Reports past year anal intercourse with a male

• Age 18 or older (reSET is only approved for use with adults)

• Person living with HIV who is an AIDS Healthcare Foundation (AHF) patient at one of the four metro areas: Atlanta, Dallas/Fort Worth, Fort Lauderdale, Los Angeles

• Screens positive for a moderate or severe stimulant use disorder in the last 3-months using the MINI

• Reports that he is not currently in drug treatment

• Currently has an active antiretroviral therapy prescription and reports \< 90% HIV Tx adherence on the 3-item Wilson measure in the past 30 days

• Can obtain access to stable internet with privacy acceptable to the participant at least twice a week

• Indicates being able to understand English (reSET is only available in English; can be read or heard)

⁃ Consents to participation in the study

⁃ Provides sufficient locator information

Locations
United States
Florida
University of Miami
RECRUITING
Miami
Contact Information
Primary
Jose Szapocznik, PhD
jszapocz@miami.edu
(305) 6105723
Time Frame
Start Date: 2025-03-04
Estimated Completion Date: 2028-01-31
Participants
Target number of participants: 500
Treatments
Experimental: reSET Group
Participants in this group will use the reSET mobile app for 12 weeks.
Other: Standard of Care Group
Participants in this group will receive standard of care treatment for 12 weeks.
Related Therapeutic Areas
Sponsors
Collaborators: National Institute on Drug Abuse (NIDA)
Leads: University of Miami

This content was sourced from clinicaltrials.gov